Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422422 · ClinicalTrials.gov registry record · Phase 2
Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.
A Phase 2 study of Epilepsy, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT00422422: Completed Phase 2 study of Epilepsy, sponsored by UCB Pharma.
NCT00422422 is a Phase 2 study of Epilepsy that has completed, run by UCB Pharma. The registered enrollment target is 100 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00422422, a Phase 2 study of Epilepsy, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
Initial study in children with epilepsy to evaluate the pharmacokinetics, safety, tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to develop dosing adaptations for future studies.
Conditions Studied
Interventions
- DRUG Brivaracetam
Study Locations (20)
Other
- 202 - Brussels
- 203 - Brussels
- 201 - Leuven
- 502 - Hradec Králové
- 504 - Ostrava Porubo
- 501 - Prague
- 602 - Aguascalientes
- 611 - Chihuahua City
Florida
- 108 - Gulf Breeze
- 110 - Miami
- 103 - Wellington
New York
- 105 - Buffalo
- 104 - Rochester
Massachusetts
- 106 - Boston
Minnesota
- 101 - Saint Paul
Missouri
- 113 - Chesterfield
Ohio
- 107 - Cincinnati
Pennsylvania
- 114 - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT00422422 record still lists
NCT00422422 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Brivaracetam is the first listed.
NCT00422422 names 20 study sites across 10 states, led by Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00422422 about?
NCT00422422 is a clinical study titled "Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.". Initial study in children with epilepsy to evaluate the pharmacokinetics, safety, tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to develop dosing adaptations for future studies.
What is the current status of trial NCT00422422?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2011-07. Estimated completion is 2013-03.
What conditions does trial NCT00422422 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00422422?
The interventions under investigation include: Brivaracetam (DRUG).
Who is sponsoring clinical trial NCT00422422?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00422422 being conducted?
This trial has 20 study locations across Florida, Massachusetts, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00422422's enrollment target sits among peer trials
100 54th of 160 higher than 103 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia